atrial natriuretic peptide (anp) , human, porcine

Carperitide acetate (Atrial Natriuretic Peptide (ANP) (1-28), human, porcine Acetate), a 28-amino acid hormone, is naturally produced and released by the human heart upon cardiac injury or mechanical stretch. This compound effectively inhibits the secretion of endothelin-1 in a dose-dependent manner.

C-Type Natriuretic Peptide (CNP) (1-22), human acetate is an agonist of natriuretic peptide receptor B (NPR-B), an endothelial-derived relaxant and growth inhibitory factor. C-Type Natriuretic Peptide (CNP) (1-22), human acetate inhibits cAMP synthesis stimulated by histamine and 5-HT or directly by Forskolin.

Amyloid β Peptide (42-1)(human) acetate is the inactive form of Amyloid β Peptide (1-42). Amyloid β Peptide (42-1)(human) acetate is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease.

GnRH Associated Peptide (GAP) (1-13), human Acetate was found to be a potent inhibitor of prolactin secretion and to stimulate the release of gonadotropins. Active immunization with peptides corresponding to GAP sequences led to greatly increased prolacti

VIP(6-28)(human, rat, porcine, bovine) acetate is an antagonist of the actions of exogenous vasoactive intestinal peptide (VIP) receptor on cAMP in the superior cervical ganglion (SCG).

PAMP-12 (human, porcine) acetate (PAMP-12 (human, porcine) acetate (196305-05-2 free base)) , a major component of ir-PAMP, is processed from the AM precursor, as is PAMP-20, and may participate in cardiovascular control.

Gastrin-Releasing Peptide, human(TFA) is a regulatory human peptide that elicits gastrin release and regulates gastric acid secretion and enteric motor function. The post-ganglionic fibers of the vagus nerve that innervate the G cells of the stomach release GRP, which stimulates the G cells to release gastrin.

Proinsulin C-peptide human acetate (Proinsulin C-peptide human acetate (33017-11-7 Free base)) is a polypeptide of 31 amino acid residues that links the A and B chains of proinsulin to ensure proper folding, has biological activity and regulates cellular functions.

Peptide YY (PYY) (3-36), human (Peptide YY (3-36)), is a gut hormone peptide that acts as a Y2 receptor agonist to reduce appetite.

C-Type Natriuretic Peptide (CNP) (1-22), human, is the 1-22 fragment of the parent C-Type Natriuretic Peptide.

Motilin (26-47), human and pig are endogenous Motilin receptor ligands in Chinese hamster ovarian cell lines, with Ki and EC50 at 2.3 nM and 0.3 nM, respectively.

Carperitide, a 28-amino acid hormone known as Atrial Natriuretic Peptide (ANP) (1-28), is naturally synthesized and released by the human heart in reaction to cardiac injury and mechanical stretch. This compound effectively suppresses endothelin-1 secretion in a dose-dependent manner.

Pegylated synthetic human C-peptide exhibits similar bioactivity to natural C-peptides (non-polyethylene glycolated) and demonstrates an extended plasma half-life, making it suitable for research in diabetic peripheral neuropathy [1].

Brain Natriuretic Peptide (1-32), rat acetate (BNP (1-32), rat acetate) is a 32-amino acid polypeptide hormone synthesized by ventricular cardiomyocytes in response to myocardial cell stretching (cardiomyocyte distension)[1].

(Met(O)27)-Glucagon (1-29) (human, rat, porcine) is a modified glucagon exhibiting the same maximum glucose-synthesizing activity in rat hepatocytes as its native form, but with reduced potency, highlighting the importance of methionine in glucagon's attachment to hepatic receptors [1].

Amyloid-β (25-35) (Aβ (25-35)) is an 11-residue fragment of the Aβ protein that retains the physical and biological characteristics of the full length peptide. It forms fibrils that react to thioflavin T and Congo red and are organized in a cross-β arrangement of β-strands similar to Aβ (1-40) and Aβ (1-42) fibrils. Aggregated Aβ (25-35) decreases the viability of rat adrenal PC12 cells. It also decreases the viability of primary rat cortical neurons at concentrations ranging from 1 nM to 30 μM. In vivo, intracerebral injection of Aβ (25-35) (20 nmol) in rats induces lesions of neuronal and tissue loss. Aggregated Aβ (25-35) administered intracerebroventricularly to rats induces learning and memory impairments in the Y-maze, novel object recognition, and contextual fear conditioning tests.

GRP (14-27) (human, porcine, canine) serves as a ligand for bombesin receptors, with specific binding inhibited by GTP and GDP, but unaffected by GMP [1].

Prolactin Releasing Peptide (1-31), human is a high affinity GPR10 ligand that cause the release of the prolactin

Glucagon-like peptide 1 (1-37), human, is a highly potent agonist of the GLP-1 receptor and a pancreatic hormone synthesized by post-translational processing of proglucagon. Unlike truncated forms of GLP-1, it neither affects food intake in rats nor enhances pancreatic insulin secretion.

CNP, a member of the natriuretic peptide family, was first identified in porcine brain and later found in other mammals as well as non-mammals. Processing of the CNP precursor gives rise to CNP-22 and its N-terminally elongated form, CNP-53. The CNPs shar

Glucagon-like peptide 1 (1-37), human (TFA), is a highly potent agonist of the GLP-1 receptor and is a pancreatic hormone synthesized through post-translational processing of proglucagon.

Biotinyl-Glucagon (1-29), encompassing human, bovine, and porcine versions, is a biotinylated form of glucagon. This peptide hormone, synthesized by the pancreas's α-cells, elevates glucose and fatty acid levels in the bloodstream [1] [2].

Atrial natriuretic peptide (3-28) (human) (ANP (3-28) (human)), a peptide hormone produced by the atrial myocardium, critically regulates blood pressure, fluid balance, and electrolyte homeostasis [1] [2].

Glucagon is a peptide hormone, produced by pancreatic α-cells. Glucagon reduces the activity of HNF-4. Glucagon stimulates gluconeogenesis. Glucagon enhances HNF4α phosphorylation.

Myelin oligodendrocyte glycoprotein (MOG) peptide, a truncated form of MOG located on the extracellular myelin sheath surface, interacts with antigen serotype HLA-DR2 to mitigate effects of ischemic stroke induced by middle cerebral artery occlusion (MCAO) in mice. In female mice, it notably reduces cortical and striatal infarct volumes, lessens sensorimotor deficits as observed in tube- and corner turn tests, enhances engagement with novel odors, and prolongs the duration of cage mate-directed vocalizations, without exhibiting similar outcomes in male mice.

Gastric inhibitory peptide 1 (GIP-1) (3-42), a fragment of the incretin hormone GIP and antagonist to the GIP receptor, is generated through the action of serum dipeptidyl peptidase 4 (DDP-4). When administered at 25 nmol/kg to an ob/ob mouse diabetes model, GIP-1 (3-42) elevates plasma glucose levels and lowers plasma insulin levels, demonstrating its effect on reducing insulin secretion from BRIN-BD11 pancreatic cells at a concentration of 100 nM.

ACTH (3-24) (human, bovine, mouse, ovine, porcine, rabbit, rat), the fragment spanning amino acids 3-24 of adrenocorticotropic hormone (ACTH), serves as a research tool in studying illnesses such as cancer, immune diseases, and cardiovascular disease [1].

(Leu31,Pro34)-Peptide YY (human) is a derivative of Peptide YY that acts as a potent and selective Y1 receptor agonist, with a dissociation constant (KD) of 1.0 nM [1].

PAMP-12(human, porcine) TFA, a significant constituent of immunoreactive (ir)-PAMP, derives from the adrenomedullin precursor and functions as a potent hypotensive peptide involved in cardiovascular regulation [1].

Dendroaspis Natriuretic Peptide, a vasodilator peptide, is derived from animal venom [1].

(Leu31,Pro34)-Peptide YY (human) (TFA) is the trifluoroacetic acid (TFA) form of (Leu31,Pro34)-Peptide YY (human), a derivative of Peptide YY that acts as a potent and selective Y1 agonist, exhibiting a dissociation constant (K D) of 1.0 nM [1].

Acetyl Gastric Inhibitory Peptide (human) TFA, a fatty acid-derivatized analog of the glucose-dependent insulinotropic polypeptide, exhibits enhanced antihyperglycemic and insulinotropic properties. It is utilized in the research of diabetes, insulin resistance, and obesity [1] [2] [3].

Brain Natriuretic Peptide-45, rat TFA (BNP-45, rat TFA) is an isoform of the rat brain natriuretic peptide extracted from the rat heart, exhibiting significant hypotensive and natriuretic effects [1].

Peptide YY (PYY) (3-36), human trifluoroacetate is a useful organic compound for research related to life sciences and the catalog number is T64716.

Galanin (2-11) amide is a synthetic peptide fragment of the neuropeptide galanin and an agonist of the galanin-2 (GAL2) receptor (EC50= 9.32 nM in a fluorescence imaging plate reader assay).1It selectively binds to the GAL2receptor (IC50= 1.76 nM for the rat receptor) over the GAL1receptor (IC50= 879 nM for the human receptor) but does also bind to the GAL3receptor (Ki= 271 nM for the rat receptor).1,2Intracerebroventricular administration of galanin (2-11) amide (1 nmol/animal) decreases immobility in the forced swim test in rats.3It also reduces the hind paw mechanical pain threshold and increases the hind paw cold sensitivity threshold in rats.1

Glucagon-Like Peptide 1 (GLP-1) (7-36)-Lys (Biotin), amide, human, is a human GLP-1 (7-36) amide biotinylated at the C-terminal.

Atrial Natriuretic Peptide (1-28), human, porcine, Biotin-labeled, is one of three mammalian natriuretic peptides (NPs) with endocrine effects on fluid homeostasis and blood pressure, holding promise for cardiovascular disease research.

Mouse Brain Natriuretic Peptide-45 (BNP-45, mouse) is a circulating variant of the mouse brain natriuretic peptide derived from the mouse heart. It exhibits powerful hypotensive and natriuretic properties.

This human neuropeptide of the RFamide peptide family with orexigenic activity may be also involved in the control of feeding behavior. The 26RFa gene is exclusively expressed in the ventromedial hypothalamic nucleus and in the lateral hypothalamic area.

Atrial Natriuretic Peptide (ANP) (1-28), rat (TFA), is the primary circulating form of ANP in rats and significantly inhibits Ang II-stimulated secretion of endothelin-1.

VIP(6-28)(human, rat, porcine, bovine) is a potent antagonist that counteracts the effects of exogenous vasoactive intestinal peptide (VIP) on cyclic adenosine monophosphate (cAMP) signaling.

Brain Natriuretic Peptide (BNP) (1-32), rat is a 32 amino acid polypeptide secreted by the ventricles of the heart in response to excessive stretching of heart muscle cells (cardiomyocytes).Brain natriuretic peptide (type B natriuretic peptide) was origin

Potent endogenous peptide agonist of Mas related GPR X2 (MRGPRX2, EC50 = 57.2 nM). Corresponds to amino acids 9 to 20 of proadrenomedullin.

Glucagon-like peptide 2 (GLP-2) is a recently identified intestinal epithelium-specific growth factor that has been shown to reduce the severity of inflammatory disorders of the intestine in rodent models. Currently Glucagon-Like Peptide 2 is used as a po

BNP-45 (rat) is a circulating form of rat brain natriuretic peptide isolated from rat heart with potent hypotensive and natriuretic potency.

Gastric inhibitory peptide (GIP) (1-42), an endogenous incretin hormone comprising 42 amino acids, promotes insulin secretion. Expressed in the intestinal neuroendocrine K cells and submandibular gland, it enters circulation after meals. GIP (1-42) blocks histamine, pentagastrin, and insulin-induced gastric acid and pepsin secretion, enhances glucose-stimulated insulin release, and accelerates gastric emptying in rats.

Klotho-derived peptide 1 (KP1) (56-87), a peptide originating from the human Klotho protein, disrupts TGF-β signaling by binding to TGF-β receptor types 1 and 2 (TGFBR1 and TGFBR2; Kds = 1.41 and 14.6 µM, respectively). Preincubation with KP1 at a concentration of 10 µg/ml hinders the TGF-β-induced escalation of fibronectin and α-smooth muscle actin (α-SMA) levels in NRK-49F rat fibroblasts. Furthermore, in vivo studies reveal that KP1, administered at 1 mg/kg per day, preferentially accumulates in damaged kidneys, leading to significant reductions in serum creatinine and blood urea nitrogen levels, indicators of improved kidney function. Additionally, it decreases kidney fibrosis in mouse models of unilateral ureteral obstruction (UUO) and unilateral ischemia-reperfusion injury-induced renal fibrosis.